Recently Featured

CAR T-Cell Therapy Unlocks Solid Tumors, Targets uPAR Surface Protein in Mice

April 2, 2026
Researchers from Memorial Sloan Kettering Cancer Center have developed a novel CAR T-cell therapy that targets the urokinase plasminogen activator receptor (uPAR) on supportive cells within the solid tumor microenvironment. This advancement addresses the longstanding challenge of CAR T-cell therapies, which have been largely ineffective against solid tumors due to their heterogeneous nature and protective…

Biogen Expands Immunology Portfolio with $5.6B Acquisition of Apellis

April 2, 2026
Biogen has announced its acquisition of Apellis Pharmaceuticals for $5.6 billion, a strategic move that significantly enhances its immunology portfolio. This deal not only secures two marketed products, Syfovre and Empaveli, but also brings in a specialized team with extensive nephrology expertise. As Biogen gears up to launch felzartamab, the addition of Apellis’ resources and…

Iterum Initiates Wind-Down After Failure to Offload Antibiotic with Sluggish Sales

April 1, 2026
Irish antibiotic specialist Iterum Therapeutics has announced the initiation of a wind-down of its operations due to limited cash reserves and the costly commercialization efforts surrounding its sole approved product, Orlynvah. This decision follows the company’s unsuccessful attempts to divest the antibiotic, which has struggled to gain traction in a competitive market. The context of…

Ongoing Cases